Summit Therapeutics (SMMT) Price & Analysis

Compare

1,684 Followers

SMMT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$15.55 - $36.91

Previous CloseN/A

Volume1.23M

Average Volume (3M)4.81M

Market Cap

$14.03B

Enterprise Value$15.51B

Total Cash (Recent Filing)$297.87M

Total Debt (Recent Filing)$5.55M

Price to Earnings (P/E)―

Beta2.34

Next Earnings

Nov 05, 2025

EPS Estimate

-0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.76

Shares Outstanding742,846,700

10 Day Avg. Volume7,953,840

30 Day Avg. Volume4,808,847

Financial Highlights & Ratios

PEG Ratio0.84

Price to Book (P/B)32.99

Price to Sales (P/S)0.00

P/FCF Ratio-90.17

Enterprise Value/Market Cap1.11

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.03K

Enterprise Value/Ebitda-20.87

Forecast

1Y Price Target

$29.25

Price Target Upside54.84% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering15

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessIvonescimab demonstrates a survival benefit where Keytruda failed, signaling a significant advantage in its class.

Market PotentialAnalyst reiterates a Buy rating with a strong conviction of ivonescimab's market potential.

Trial ResultsThe HARMONi trial showed ivonescimab translating robust progression-free survival into overall survival, boosting confidence in its success.

Bears Say

Investor ConcernsExpect pressure to shares of SMMT given the outcomes and critical discussion at WCLC.

Regulatory ChallengesFDA approval of ivonescimab in EGFRm NSCLC is highly unlikely and HARMONi failed to validate the HARMONi-A signal observed in China.

Strategic PositioningSummit is considered poorly positioned for medium and long-term success with ivonescimab without a partner.

Summit Therapeutics News

Summit Therapeutics initiated with an Underweight at Barclays

Barclays initiated coverage of Summit Therapeutics (SMMT) with an Underweight rating and $13 price target The firm’s cautious...

6d ago

SMMT

Summit Therapeutics initiated with an Underweight at Barclays

Barclays initiated coverage of Summit Therapeutics (SMMT) with an Underweight rating and $13 price target Published first on...

6d ago

SMMT

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

11d ago

AMGN

SMMT

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

12d ago

AMGN

SMMT

Summit Therapeutics falls -24.1%

Summit Therapeutics (SMMT) is down -24.1%, or -$6.27 to $19.71. Published first on TheFly – the ultimate source...

14d ago

SMMT

EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz

The major averages were broadly higher near noon, recovering ground after Friday’s pullback as investors grow increasingly confident...

14d ago

Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX

Stock futures started the week with a quiet lift, recovering ground after Friday’s pullback as investors grew increasingly...

15d ago

EME

DNTH

Summit Therapeutics announces data from Phase III HARMONi trial

Summit Therapeutics (SMMT) announced data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific...

15d ago

SMMT

Apple upgraded, AMD downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

19d ago

AMD

BAM

Guggenheim starts Summit Therapeutics at Buy, sees ‘multi-fold upside potential’

As previously reported, Guggenheim initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $40 price target....

19d ago

MRK

SMMT

Summit Therapeutics’ Ivonescimab Shows Promising Trial Results, Offering a Risk-Mitigation Opportunity with a Buy Rating

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Summit Therapeutics today and set a price target...

7d ago

SMMT

Summit Therapeutics Reveals Promising Phase III Trial Results

Summit Therapeutics ( ($SMMT) ) just unveiled an announcement. On September 7, 2025, Summit Therapeutics announced promising data...

15d ago

SMMT

Summit Therapeutics’ Ivonescimab: Promising Efficacy and Market Potential Reinforce Buy Rating

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Summit Therapeutics. The associated price target...

15d ago

SMMT

Positive Buy Rating for Summit Therapeutics Driven by Promising HARMONi Trial Results and Anticipated Stock Upside

UBS analyst David Dai has maintained their bullish stance on SMMT stock, giving a Buy rating yesterday. David...

15d ago

SMMT

SMMT FAQ

What was Summit Therapeutics’s price range in the past 12 months?

Summit Therapeutics lowest stock price was $15.55 and its highest was $36.91 in the past 12 months.

What is Summit Therapeutics’s market cap?

Summit Therapeutics’s market cap is $14.03B.

When is Summit Therapeutics’s upcoming earnings report date?

Summit Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 43 days.

How were Summit Therapeutics’s earnings last quarter?

Summit Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.091 by -$0.669.

Is Summit Therapeutics overvalued?

According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Summit Therapeutics pay dividends?

Summit Therapeutics does not currently pay dividends.

What is Summit Therapeutics’s EPS estimate?

Summit Therapeutics’s EPS estimate is -0.17.

How many shares outstanding does Summit Therapeutics have?

Summit Therapeutics has 742,846,700 shares outstanding.

What happened to Summit Therapeutics’s price movement after its last earnings report?

Summit Therapeutics reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.091. Following the earnings report the stock price went down -9.097%.

Which hedge fund is a major shareholder of Summit Therapeutics?

Currently, no hedge funds are holding shares in SMMT

Summit Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-328.30%

Trailing 12-Months

Asset Growth

-5.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Summit Therapeutics

Summit Therapeutics (SMMT) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibiotics to combat infections caused by multi-drug resistant bacteria. The company operates in the healthcare sector, with a primary focus on developing new treatments for infectious diseases through its innovative pipeline of antibiotic candidates.

Summit Therapeutics (SMMT) Earnings & Revenues

Historic Earnings Reports

SMMT Company Deck

SMMT Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted several significant achievements, particularly the approval of ivonescimab in China and successful clinical trial results, indicating a promising outlook for Summit Therapeutics. Despite some concerns over increased operating expenses and uncertainty in OS benefit, the sentiment remains largely optimistic.View all SMMT earnings summaries

SMMT Stock 12 Month Forecast

Average Price Target

$29.25

▲(54.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","21":"$21","31":"$31","41":"$41","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21,31,41,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.84,25.852307692307694,27.864615384615384,29.876923076923077,31.88923076923077,33.901538461538465,35.91384615384615,37.926153846153845,39.93846153846154,41.95076923076923,43.963076923076926,45.97538461538461,47.98769230769231,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.84,24.256153846153847,24.672307692307694,25.088461538461537,25.504615384615384,25.92076923076923,26.336923076923078,26.75307692307692,27.16923076923077,27.585384615384616,28.001538461538463,28.417692307692306,28.833846153846153,{"y":29.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.84,22.92923076923077,22.018461538461537,21.107692307692307,20.196923076923078,19.286153846153844,18.375384615384615,17.464615384615385,16.553846153846152,15.643076923076922,14.732307692307693,13.821538461538461,12.91076923076923,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >